covidien corporate overview n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Covidien: Corporate Overview PowerPoint Presentation
Download Presentation
Covidien: Corporate Overview

Loading in 2 Seconds...

play fullscreen
1 / 20

Covidien: Corporate Overview - PowerPoint PPT Presentation


  • 205 Views
  • Uploaded on

Covidien: Corporate Overview. Who We Are. 42,000 employees. 50,000 different medical products. $ 11 billion company. Top 10 healthcare company. Covidien is …. A global medical device and pharmaceutical manufacturing company with nearly $ 11 billion in annual revenue

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Covidien: Corporate Overview' - sauda


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
who we are
Who We Are

42,000 employees

50,000 different medical products

$11 billion company

Top 10 healthcare company

slide3

Covidien is …

  • A global medical device and pharmaceutical manufacturing company with nearly $11 billion in annual revenue
  • Well positioned with a diverse portfolio of products and technologies in attractive franchises
  • A company with a committed to quality and innovation; dedicated to clinical solutions
  • Highly efficient and productive, producing strong margins and cash flow
  • A leading player across our portfolio
our mission and goal
Our Mission and Goal

Our Mission

Create and deliver innovative healthcare solutions, developed in ethical collaboration with medical professionals, which enhance the quality of life for patients and improve outcomes for our customers and our shareholders.

Our Goal

Become the leading global healthcare products company by creating innovative medical solutions for better patient outcomes and delivering value through clinical leadership and excellence in everything we do.

our values
Our Values

We each take responsibility for delivering outstanding results to our partners, patients and teammates, while affirming our commitment to integrity and the highest standards of ethical conduct.

Accountability

We are integral partners working with our colleagues and customers to generate innovative ideas that solve challenging healthcare problems.

Collaboration

We are caring professionals committed to improving the health and well-being of patients around the world.

Compassion

We strive to fully understand our marketplace, our customers, our communities and our employees, and to enter into relationships with a sense of honesty, fairness and trust.

Diversity

strategic focus areas for covidien
Strategic Focus Areas for Covidien

Maintain a customer mindset in everything we do.

We consistently act with our customer in mind and strive to understand their needs. We collaborate with both internal and external customers to create innovative solutions for better outcomes.

Innovate for better outcomes

We are committed to developing

approaches and solutions throughout the organization that address unmet needs. We will challenge ourselves to think, listen and act differently to drive creativity in everything we do.

Customer Focus

Innovation

Globalize to accelerate growth

We seek to understand local requirements and needs to develop product portfolios that are relevant to the markets we serve. We leverage the full potential of our diverse workforce to employ a global mindset and infrastructure to maximize the Company’s potential throughout the world.

Focus on communication and execution

aligned to the Company’s mission

We provide employees the information and tools to accelerate the execution of our

objectives. We promote consistent accountability and encourage people to take risks.

High-PerformanceOrganization

Globalization

covidien is committed to
Covidien is Committed to…

Managing portfolio for growth, margin and ROIC expansion

Continuing to build new product flow with clinically relevant offerings

Focusing on BD&L activity that complements current franchises

Recruiting and retaining top talent throughout the organization

Assuring commitment to service, quality and compliance

Maintaining strong balance sheet and ample cash flow to support growth, investments and shareholder interests

intense focus on innovation
Intense Focus On Innovation

Doubled annual patent filings since 2004

Creating more intellectual property and more aggressively protecting our technology

Launched an Innovation Council and Innovation

Awards program

Increased R&D investments from $262MM in 2006 to $438MM in 2009

Sales from new products increased 3X since 2006

experienced management team
Experienced Management Team

Rich Meelia

President, CEO

Joe Almeida

President,

Medical Devices

Amy Wendell

SVP,

Business Development

Chuck Dockendorff

EVP,

Chief Financial

Officer

Tim Wright

President,

Pharmaceuticals

& Imaging

John Masterson

SVP,

General Counsel

Jim Muse

SVP,

Global Supply Chain

Jim Clemmer

President,

Medical Supplies

Mike Dunford

SVP,

Human Resources

Eric Kraus

SVP,

Corp. Communications

Our management team averages over 25 years of healthcare and/or functional experience

segment overview
Segment Overview
  • Surgical Devices
  • Energy-based Devices
  • Respiratory and Monitoring Solutions
  • Vascular Therapies

Medical Devices

Pharmaceutical & Imaging Products

  • Specialty Pharmaceuticals
  • Active Pharmaceutical Ingredients
  • Radiopharmaceuticals
  • Contrast Products
  • Nursing Care
  • Monitoring & OR Products
  • SharpSafety
  • Original Equipment Manufacture

Medical Supplies

slide11

2009 Sales by Business Segment$11 Billion

Pharmaceuticals

Medical Supplies

  • Dosage Pharmaceuticals
  • Active Pharmaceutical Ingredients
  • Radiopharmaceuticals
  • Contrast Agents

27%

  • Nursing Care
  • SharpSafety
  • Monitoring & OR Products
  • Original Equipment Manufacture

16%

Medical Supplies

$0.9B

57%

Medical Devices

  • Surgical Devices
  • Energy-based Devices
  • Respiratory and Monitoring Solutions
  • Vascular Therapies
slide12

2009 Net Sales by Business Segment$11 Billion

Pharmaceutical Products

$2.9B

Medical Supplies

$1.7B

  • Dosage Pharmaceuticals
  • Active Pharmaceutical Ingredients
  • Radiopharmaceuticals
  • Contrast Agents
  • Nursing Care
  • SharpSafety
  • Monitoring & OR Products
  • Original Equipment Manufacturer

27%

16%

57%

Medical Devices

$6.1B

  • Surgical Devices
  • Energy-based Devices
  • Respiratory and Monitoring Solutions
  • Vascular Therapies
slide13

2009 Net Sales by Geography$11 Billion

Other

Americas

$0.6B

Asia-Pacific

$1.4B

United States

$6.2B

Europe

$2.6B

covidien s origin
Covidien’s Origin

Year

Major Acquisitions

Specialty

Wound Care, Urology, Vascular Compression, Incontinent Care

1994

Needles & Syringes, Sutures, Dialysis, Enteral Feeding

1998

Wound Closure, Laparoscopic Instruments, Electrosurgery

1998

Respiratory, Imaging and Pharmaceutical

2000

Acquired numerous smaller companies from 1996 – present

economic environment
Economic Environment

Unprecedented recent foreign exchange volatility

U.S. recession and global economic slowdown

Restricted credit availability

Raw material prices

covidien well positioned
Covidien Well Positioned

Broad product line across multiple healthcare categories

Less than 5% of revenues are considered capital equipment

Modest exposure to elective surgical procedures

Global footprint and growing non-US business

Strong balance sheet, ample cash on hand, good cash flow generation

medical devices update
Medical Devices Update
  • 2009 sales growth 2% (8% operational)
  • Strong growth in endomechanical, soft tissue repair, vascular and energy
  • VNUS, Bacchus and Aspect acquisitions integrated and contributing to growth
  • ev3 acquisition expected to provide access to new markets
  • Focus on bariatric, hernia and biosurgery growth initiatives; vascular expansion; emerging market opportunities
  • Recent 2010 launches: new SILS™ instruments, next generation EGIA Universal, hemorrhoid stapler

* Operational growth, net sales growth excluding the impact of foreign currency exchange, is a non-GAAP measure.

pharmaceuticals update
Pharmaceuticals Update
  • Acquired proven, patented drug technology to build pipeline
  • Developing capabilities in formulation, regulatory, clinical development and Risk Evaluation & Mitigation Strategies (REMS)
  • Expanding commercial sales force and medical affairs to market licensed products in branded pain
  • Maria announcement will help ease moly shortage, but supply chain remains fragile and unpredictable
    • New product releases:
medical supplies update
Medical Supplies Update
  • 2009 sales growth (2%) (flat operational)
  • Broad portfolio with many products #1 or #2 in their markets
  • Continue to sell value beyond price in many commoditized markets
  • Pruning portfolio of lower margin, slow growth offerings
  • Managing business with minimal investment for cash and ROIC